• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Xtant Medical Holdings Inc.

    2/17/26 12:57:35 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XTNT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Xtant Medical Holdings, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    98420P308

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    98420P308


    1Names of Reporting Persons

    LYTTON LAURENCE W
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    675,898.00
    6Shared Voting Power

    7,026,104.00
    7Sole Dispositive Power

    675,898.00
    8Shared Dispositive Power

    7,026,104.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,702,002.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Percentage calculated based on 140,004,240 shares of Common Stock outstanding on November 7, 2025, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended September 30, 2025.


    SCHEDULE 13G

    CUSIP No.
    98420P308


    1Names of Reporting Persons

    LYTTON-KAMBARA FOUNDATION
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,026,104.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,026,104.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,026,104.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Percentage calculated based on 140,004,240 shares of Common Stock outstanding on November 7, 2025, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended September 30, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Xtant Medical Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    664 Cruiser Lane, Belgrade, MT 59714
    Item 2. 
    (a)Name of person filing:

    Laurence W. Lytton Lytton-Kambara Foundation
    (b)Address or principal business office or, if none, residence:

    467 Central Park West New York, NY 10025
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    98420P308
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Lytton: 7,702,002 Foundation: 7,026,104
    (b)Percent of class:

    Lytton: 5.5% Foundation: 5.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Lytton: 675,898 Foundation: 0

     (ii) Shared power to vote or to direct the vote:

    Lytton: 7,026,104 Foundation: 7,026,104

     (iii) Sole power to dispose or to direct the disposition of:

    Lytton: 675,898 Foundation: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Lytton: 7,026,104 Foundation: 7,026,104

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    LYTTON LAURENCE W
     
    Signature:/s/ Laurence W. Lytton
    Name/Title:Reporting Person
    Date:02/17/2026
     
    LYTTON-KAMBARA FOUNDATION
     
    Signature:/s/ Laurence W. Lytton
    Name/Title:President
    Date:02/17/2026
    Exhibit Information

    EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

    Get the next $XTNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XTNT

    DatePrice TargetRatingAnalyst
    12/5/2023$2.00Buy
    BTIG Research
    More analyst ratings

    $XTNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Brandt Kevin D bought $49,837 worth of shares (41,670 units at $1.20), increasing direct ownership by 5% to 815,860 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    11/17/23 4:42:41 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Xtant Medical with a new price target

    BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00

    12/5/23 8:12:02 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft

    nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mont., Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™. nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with hi

    12/11/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Companion Spine LLC Completes Acquisition of the Business and Assets of Paradigm Spine GmbH, including the Coflex® and CoFix® Spine Implants and All Other Implant Systems, from Xtant™ Medical Holdings, Inc.

    Companion Spine is the first company in the world with a product portfolio solely focused on Total Disease State Solutions™ ("TDS™") for degenerative spine diseases. This acquisition creates the world's largest and most comprehensive product portfolio of minimally invasive surgical ("MIS") Posterior Dynamic Solutions™ of spine stabilization and motion preserving implants. The combined company can now treat the full range of lumbar spinal stenosis ("LSS") and degenerative disc disease ("DDD") conditions across the spectrum of disease progression with our SMART™ (Solution Based, Minimal Access, Reliable Technologies) portfolio. Companion Spine LLC ("Companion Spine" or "the Company")

    12/1/25 4:21:00 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine

    BELGRADE, Mont., Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that the company has completed its previously announced sale of certain non-core Coflex® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC, and its affiliates. The purchase price of the transaction was approximately $19.2 million, consisting of $11.0 million in cash and $8.2 million in short-term seller financing in the form of

    12/1/25 4:05:00 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Xtant Medical Holdings Inc.

    SCHEDULE 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    2/17/26 12:57:35 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Xtant Medical Holdings Inc.

    8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    1/16/26 4:15:32 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Holdings Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    12/3/25 4:05:52 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Assistant Secretary Neils Scott C covered exercise/tax liability with 8,084 shares, decreasing direct ownership by 0.95% to 843,381 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    1/16/26 5:00:16 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Director Bakewell John K was granted 158,228 shares, increasing direct ownership by 21% to 914,116 units (SEC Form 4)

    4/A - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    11/18/25 5:53:42 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Vizirgianakis Stavros G. was granted 553,797 shares, increasing direct ownership by 8% to 7,515,570 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    11/18/25 5:34:08 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Announces Board Leadership Transition

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

    5/9/24 7:00:00 AM ET
    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

    BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va

    5/18/23 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Appoints Mark Schallenberger as Chief Operations Officer

    BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. "We are thrilled to have Mark rejoin the team as we reinvent Xtant," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark's contributio

    1/9/23 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Financials

    Live finance-specific insights

    View All

    Xtant Medical Reports Third Quarter 2025 Financial Results

    Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Growth of 11%-15% over FY24 Previously Announced Sale of Certain Hardware Assets and OUS Businesses to Companion Spine Anticipated to Close by Year-End BELGRADE, Mont., Nov. 10, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the third quarter ended September 30, 2025.

    11/10/25 4:28:00 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025

    BELGRADE, Mont., Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the start of trading on Tuesday, November 11, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial officer, will host a conference call at 8:30am ET on that day. Conference Details: Conference Date: Tuesday, Nov

    11/4/25 8:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xtant Medical Reports Second Quarter 2025 Financial Results

    Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont., Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue

    8/12/25 7:00:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $XTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Xtant Medical Holdings Inc.

    SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    9/10/24 4:12:57 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Xtant Medical Holdings Inc. (Amendment)

    SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    2/13/24 5:10:19 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Xtant Medical Holdings Inc. (Amendment)

    SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)

    8/3/23 4:59:55 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care